ProfessorSebastian Johnston
Professor of Respiratory Medicine & Allergy
National Heart & Lung Institute - Faculty of Medicine
Orcid identifier0000-0003-3009-9200 (opens in a new tab)
- Professor of Respiratory Medicine & AllergyNational Heart & Lung Institute - Faculty of Medicine
- 02075943764 (Work)
- 343, Norfolk Place, St Mary's Campus, United Kingdom
BIO
Sebastian Johnston is Professor of Respiratory Medicine & Allergy at the National Heart and Lung Institute, Imperial College London, and Honorary Consultant Physician in Respiratory Medicine & Allergy at St Mary's Hospital, Imperial Healthcare NHS Trust, London. He is the Clinical Academic Training Lead for Respiratory Medicine at Imperial College & Imperial Healthcare NHS Trust. He is an Emeritus NIHR Senior Investigator.
He is past Director of the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, was the Asthma UK Clinical Professor and was Chairman of the Infection Groups in both the European Respiratory Society and the European Academy of Allergy and Clinical Immunology and of the Asthma Section, European Academy of Allergy and Clinical Immunology.
He was Editor of Thorax 2002-2010 and serves on the Editorial Boards of several other respiratory and allergy journals. He has served on several ERC, MRC and NIH panels. He receives/has received grant support from the European Research Council (Advanced Research Grants), the MRC (Centre, Programme and Project Grants), the Wellcome Trust (Centre and Project Grants), Asthma UK, British Lung Foundation (Programme Grant), BMA, ERS, EAACI and NIH.
Notable discoveries that have emerged from his work include establishing the viral (mostly rhinovirus) aetiology of asthma and COPD exacerbations (BMJ, Lancet), demonstrating that people with asthma and COPD are more susceptible to virus infections (Lancet, PNAS), discovering novel mechanisms of susceptibility to virus infection in asthma and COPD (JEM, Nature Med) and describing a novel and effective treatment approach for acute exacerbations of asthma (NEJM).
His work has led to the publishing of many patents, the licensing of these patents to industry and to completion of Phase I & II clinical studies on the use of IFN-beta for treatment of acute exacerbations of asthma. His rhinovirus vaccine will enter Phase I studies in late 2024/early 2025.
He is past Director of the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, was the Asthma UK Clinical Professor and was Chairman of the Infection Groups in both the European Respiratory Society and the European Academy of Allergy and Clinical Immunology and of the Asthma Section, European Academy of Allergy and Clinical Immunology.
He was Editor of Thorax 2002-2010 and serves on the Editorial Boards of several other respiratory and allergy journals. He has served on several ERC, MRC and NIH panels. He receives/has received grant support from the European Research Council (Advanced Research Grants), the MRC (Centre, Programme and Project Grants), the Wellcome Trust (Centre and Project Grants), Asthma UK, British Lung Foundation (Programme Grant), BMA, ERS, EAACI and NIH.
Notable discoveries that have emerged from his work include establishing the viral (mostly rhinovirus) aetiology of asthma and COPD exacerbations (BMJ, Lancet), demonstrating that people with asthma and COPD are more susceptible to virus infections (Lancet, PNAS), discovering novel mechanisms of susceptibility to virus infection in asthma and COPD (JEM, Nature Med) and describing a novel and effective treatment approach for acute exacerbations of asthma (NEJM).
His work has led to the publishing of many patents, the licensing of these patents to industry and to completion of Phase I & II clinical studies on the use of IFN-beta for treatment of acute exacerbations of asthma. His rhinovirus vaccine will enter Phase I studies in late 2024/early 2025.
FACULTY
- Faculty of Medicine
POSITION NAME
- Professor of Respiratory Medicine & Allergy